Advisors Capital Management LLC Has $43.69 Million Stake in Medtronic PLC $MDT

Key Points

• Advisors Capital Management LLC increased its Medtronic stake by 4.5% in Q4 to 454,855 shares, worth $43.69 million.
• Medtronic has bolstered its strategic footprint by completing the CathWorks acquisition and investing $100M in Pulnovo, expanding its AI and cardiovascular diagnostics/therapy pipeline and supporting longer‑term growth areas like automated insulin delivery and home healthcare.
• Near‑term headwinds include analyst caution (mixed Buy/Hold views and a UBS bearish call), pre‑earnings expectations of a single‑digit profit decline, and the stock trading below its 50‑ and 200‑day averages while paying a 3.4% yield

Advisors Capital Management LLC grew its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 454,855 shares of the medical technology company's stock after purchasing an additional 19,479 shares during the period. Advisors Capital Management LLC's holdings in Medtronic were worth $43,693,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Corundum Trust Company INC acquired a new position in Medtronic in the third quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new position in Medtronic in the fourth quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new position in Medtronic in the third quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new position in Medtronic during the fourth quarter valued at approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in Medtronic during the 4th quarter worth $29,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks acquisition and $100M investment in Pulnovo expand Medtronic’s AI and cardiovascular diagnostics/therapy footprint — these moves boost long‑term addressable market and product pipeline relevance. Medtronic Expands AI Heart Care As Investors Weigh Valuation And Momentum
• Positive Sentiment: Market reports highlight sizable growth opportunities (automated insulin delivery, catheters, long‑term/home healthcare) where Medtronic is a listed participant — supports longer‑term revenue runway assumptions. 2026 HoustonCISO ORBIE Awards Recognize Top Security Executives
• Neutral Sentiment: Analysts (Jefferies) reiterate a Hold with a $95 target, reflecting valuation compression and a slower growth outlook; not a catalyst for a large rerating but keeps expectations muted. Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
• Neutral Sentiment: Investor interest pieces and valuation checks note new GE HealthCare tie‑ups and the Altaviva launch — positive strategic context but likely already priced in and awaiting earnings results for confirmation. Medtronic (MDT) Valuation Check As New GE HealthCare Tie Up And Altaviva Launch Draw Investor Interest
• Negative Sentiment: Pre‑earnings coverage flags an expected single‑digit drop in quarterly profits — raises the risk of a downside surprise and is a chief near‑term pressure on the stock. What You Need to Know Ahead of Medtronic's Earnings Release
• Negative Sentiment: UBS issued a pessimistic forecast for MDT’s stock price — an explicit bearish view that can amplify selling pressure, particularly with earnings imminent. UBS Group Issues Pessimistic Forecast for Medtronic NYSE: MDT Stock Price
• Negative Sentiment: Several investor commentaries (including Seeking Alpha) maintain a Hold view citing slow growth, high debt and competitive pressures (HUGO robotics, diabetes spin‑off uncertainties), signaling limited near‑term upside without clearer execution. Medtronic: Is This Dividend Aristocrat Finally A "Buy" Before Earnings?

Medtronic Stock Performance

Medtronic stock opened at $83.36 on Friday. The stock has a 50-day simple moving average of $89.78 and a 200 day simple moving average of $95.23. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.93 and a 12-month high of $106.33. The stock has a market capitalization of $107.03 billion, a price-to-earnings ratio of 23.22, a P/E/G ratio of 2.18 and a beta of 0.75.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date was Friday, March 27th. Medtronic's dividend payout ratio (DPR) is presently 79.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MDT shares. Needham & Company LLC restated a "buy" rating and set a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Stifel Nicolaus dropped their target price on shares of Medtronic from $105.00 to $95.00 and set a "hold" rating on the stock in a research report on Monday, April 6th. CICC Research assumed coverage on Medtronic in a research report on Friday, January 30th. They issued an "outperform" rating for the company. Citigroup reduced their target price on Medtronic from $117.00 to $110.00 and set a "buy" rating for the company in a research report on Tuesday, April 7th. Finally, Barclays lifted their price objective on Medtronic from $118.00 to $120.00 and gave the company an "overweight" rating in a report on Wednesday, April 1st. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $107.80.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.